Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for HALO

Stock NameHalozyme Therapeutics Inc
TickerHALO(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS40637H1095
LEI529900242I3SV9AGM753

Show aggregate HALO holdings

News associated with HALO

Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of “Hold” from Analysts
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been assigned a consensus rating of “Hold” from the eleven research firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and four have issued a buy recommendation on the […] - 2025-08-26 02:16:51
Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week High Following Analyst Upgrade
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday after Morgan Stanley raised their price target on the stock from $75.00 to $80.00. Morgan Stanley currently has an overweight rating on the stock. Halozyme Therapeutics traded as high as $70.70 and last traded at […] - 2025-08-20 02:34:49
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Lessened by Vanguard Group Inc.
Vanguard Group Inc. trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 3.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,831,503 shares of the biopharmaceutical company’s stock after selling 450,211 shares during […] - 2025-08-13 05:43:01
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. decreased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,748,851 shares of the biopharmaceutical company’s stock after selling 34,326 shares during […] - 2025-08-12 05:24:49
Halozyme Therapeutics (NASDAQ:HALO) Upgraded to “Overweight” at Morgan Stanley
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report released on Wednesday, Marketbeat Ratings reports. The brokerage currently has a $75.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $62.00. Morgan Stanley’s […] - 2025-08-08 02:40:46
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Holdings Boosted by LPL Financial LLC
LPL Financial LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 17.1% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 242,432 shares of the biopharmaceutical company’s stock after acquiring an additional 35,429 shares during the period. LPL Financial LLC’s holdings in […] - 2025-08-07 04:46:47
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $62.70 Consensus Price Target from Analysts
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have earned an average recommendation of “Hold” from the twelve analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating on the company. […] - 2025-08-04 02:59:02
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by IFP Advisors Inc
IFP Advisors Inc increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2,374.1% during the first quarter, HoldingsChannel.com reports. The fund owned 2,103 shares of the biopharmaceutical company’s stock after buying an additional 2,018 shares during the period. IFP Advisors Inc’s holdings in Halozyme Therapeutics were worth $134,000 as of its most […] - 2025-07-29 04:32:50
Envestnet Asset Management Inc. Acquires 1,161 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Envestnet Asset Management Inc. raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 0.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 303,774 shares of the biopharmaceutical company’s stock after acquiring an additional 1,161 shares during […] - 2025-07-17 04:50:57
Teacher Retirement System of Texas Sells 3,278 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Teacher Retirement System of Texas trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 8.7% in the first quarter, Holdings Channel reports. The institutional investor owned 34,238 shares of the biopharmaceutical company’s stock after selling 3,278 shares during the quarter. Teacher Retirement System of Texas’ holdings in Halozyme Therapeutics were worth $2,185,000 […] - 2025-07-10 05:14:10
Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $61.90
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has received a consensus rating of “Hold” from the twelve research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating on the company. The average […] - 2025-07-10 03:07:07
Principal Financial Group Inc. Has $24.25 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Principal Financial Group Inc. grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 380,021 shares of the biopharmaceutical company’s stock after buying an additional 3,826 shares during the quarter. Principal Financial Group […] - 2025-07-09 05:51:39
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 39.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,742 shares of the biopharmaceutical company’s stock after selling 3,153 shares during the quarter. Vontobel Holding Ltd.’s holdings in Halozyme […] - 2025-07-09 05:00:49
Envestnet Portfolio Solutions Inc. Has $721,000 Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Envestnet Portfolio Solutions Inc. lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 35.2% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,292 shares of the biopharmaceutical company’s stock after selling 6,143 shares during the period. Envestnet Portfolio Solutions Inc.’s […] - 2025-06-26 04:38:48
Janney Montgomery Scott LLC Grows Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Janney Montgomery Scott LLC boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 294,123 shares of the biopharmaceutical company’s stock after purchasing an additional 6,392 shares during […] - 2025-06-19 05:50:56
SeaCrest Wealth Management LLC Invests $213,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
SeaCrest Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,333 shares of the biopharmaceutical company’s stock, valued at approximately $213,000. Several other institutional […] - 2025-06-09 05:54:51
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Wellington Management Group LLP
Wellington Management Group LLP lessened its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 12.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 57,370 shares of the biopharmaceutical company’s stock after selling 7,787 shares during the quarter. Wellington Management Group LLP’s holdings in Halozyme Therapeutics were worth $2,743,000 at the […] - 2025-06-06 05:34:51
Tidal Investments LLC Has $381,000 Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Tidal Investments LLC trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 61.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,978 shares of the biopharmaceutical company’s stock after selling 12,598 shares during the period. Tidal Investments LLC’s holdings […] - 2025-05-30 05:47:04
Friday's ETF with Unusual Volume: GFLW
The VictoryShares Free Cash Flow Growth ETF is seeing unusually high volume in afternoon trading Friday, with over 2.9 million shares traded versus three month average volume of about 196,000. Shares of GFLW were up about 0.7% on the day. Components of that ETF with the highes - 2025-05-16 16:18:34
Baird Financial Group Inc. Buys 221 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Baird Financial Group Inc. raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,119 shares of the biopharmaceutical company’s stock after acquiring an additional 221 shares during the period. […] - 2025-05-16 05:31:14
Halozyme Therapeutics Reaches Analyst Target Price
In recent trading, shares of Halozyme Therapeutics Inc (Symbol: HALO) have crossed above the average analyst 12-month target price of $68.12, changing hands for $70.14/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgra - 2025-05-08 09:19:58
Hsbc Holdings PLC Acquires 3,289 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Hsbc Holdings PLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 52.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,615 shares of the biopharmaceutical company’s stock after purchasing an additional 3,289 shares during the quarter. Hsbc […] - 2025-05-08 05:10:47
Halozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High After Strong Earnings
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a stronger than expected earnings report. The company traded as high as $69.07 and last traded at $68.06, with a volume of 1856311 shares trading hands. The stock had previously closed at $59.38. The […] - 2025-05-08 03:08:54
4,426 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by Marshall Wace LLP
Marshall Wace LLP bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund bought 4,426 shares of the biopharmaceutical company’s stock, valued at approximately $212,000. Other institutional investors and hedge funds have also made changes to their positions in the company. Heck […] - 2025-05-06 04:30:49
Halozyme Files Patent Infringement Lawsuit Against Merck
(RTTNews) - Halozyme Therapeutics (HALO) filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. in U.S. District Court in New Jersey. Halozyme believes the subcutaneous formulation of Merck's cancer medicine, Keytruda, infringes multiple patents that Halozyme filed - 2025-04-24 10:08:04
Legal & General Group Plc Decreases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Legal & General Group Plc lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 225,427 shares of the biopharmaceutical company’s stock after selling 3,197 shares during the quarter. Legal & General Group Plc’s holdings in Halozyme Therapeutics were worth $10,778,000 […] - 2025-04-17 06:08:53
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by CIBC Private Wealth Group LLC
CIBC Private Wealth Group LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 99.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,053 shares of the biopharmaceutical company’s stock after selling 963,451 shares during […] - 2025-04-08 05:22:55
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by California Public Employees Retirement System
California Public Employees Retirement System cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 6.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 213,687 shares of the biopharmaceutical company’s stock after selling 15,172 shares during the quarter. […] - 2025-04-07 05:56:55
Schroder Investment Management Group Sells 9,933,836 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Schroder Investment Management Group cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 99.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 87,503 shares of the biopharmaceutical company’s stock after selling 9,933,836 shares during the quarter. Schroder Investment Management […] - 2025-04-06 05:30:52

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc HALO holdings

DateNumber of HALO Shares HeldBase Market Value of HALO SharesLocal Market Value of HALO SharesChange in HALO Shares HeldChange in HALO Base ValueCurrent Price per HALO Share HeldPrevious Price per HALO Share Held
2025-11-12 (Wednesday)47,537HALO holding decreased by -156USD 3,357,538HALO holding increased by 12828USD 3,357,538-156USD 12,828 USD 70.63 USD 70.13
2025-11-11 (Tuesday)47,693USD 3,344,710HALO holding increased by 101109USD 3,344,7100USD 101,109 USD 70.13 USD 68.01
2025-11-10 (Monday)47,693USD 3,243,601HALO holding decreased by -10969USD 3,243,6010USD -10,969 USD 68.01 USD 68.24
2025-11-07 (Friday)47,693USD 3,254,570HALO holding decreased by -7154USD 3,254,5700USD -7,154 USD 68.24 USD 68.39
2025-11-06 (Thursday)47,693HALO holding decreased by -156USD 3,261,724HALO holding decreased by -6363USD 3,261,724-156USD -6,363 USD 68.39 USD 68.3
2025-11-05 (Wednesday)47,849HALO holding decreased by -1560USD 3,268,087HALO holding decreased by -94195USD 3,268,087-1,560USD -94,195 USD 68.3 USD 68.05
2025-11-04 (Tuesday)49,409HALO holding decreased by -312USD 3,362,282HALO holding increased by 70752USD 3,362,282-312USD 70,752 USD 68.05 USD 66.2
2025-11-03 (Monday)49,721HALO holding decreased by -312USD 3,291,530HALO holding increased by 29879USD 3,291,530-312USD 29,879 USD 66.2 USD 65.19
2025-10-31 (Friday)50,033USD 3,261,651HALO holding increased by 28018USD 3,261,6510USD 28,018 USD 65.19 USD 64.63
2025-10-30 (Thursday)50,033USD 3,233,633HALO holding decreased by -31521USD 3,233,6330USD -31,521 USD 64.63 USD 65.26
2025-10-29 (Wednesday)50,033USD 3,265,154HALO holding decreased by -7004USD 3,265,1540USD -7,004 USD 65.26 USD 65.4
2025-10-28 (Tuesday)50,033HALO holding increased by 468USD 3,272,158HALO holding increased by 8303USD 3,272,158468USD 8,303 USD 65.4 USD 65.85
2025-10-27 (Monday)49,565USD 3,263,855HALO holding decreased by -14870USD 3,263,8550USD -14,870 USD 65.85 USD 66.15
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of HALO by Blackrock for IE00B3VWM098

Show aggregate share trades of HALO

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-12SELL-15671.80069.540 69.766USD -10,883 58.29 Loss of -1,790 on sale
2025-11-06SELL-15670.49067.395 67.704USD -10,562 58.07 Loss of -1,502 on sale
2025-11-05SELL-1,56070.49067.800 68.069USD -106,188 58.02 Loss of -15,674 on sale
2025-11-04SELL-31269.91065.000 65.491USD -20,433 57.97 Loss of -2,347 on sale
2025-11-03SELL-31266.38164.720 64.886USD -20,244 57.93 Loss of -2,172 on sale
2025-10-28BUY46865.40066.250 66.165USD 30,965 57.77
2025-10-24SELL-15666.15067.280 67.167USD -10,478 57.68 Loss of -1,480 on sale
2025-10-15BUY93666.36067.620 67.494USD 63,174 57.33
2025-10-02BUY15671.69075.500 75.119USD 11,719 57.18
2025-09-30BUY31273.34074.930 74.771USD 23,329 56.98
2025-09-11BUY62477.53077.580 77.575USD 48,407 56.45
2025-08-21SELL-12271.61072.330 72.258USD -8,815 56.36 Loss of -1,939 on sale
2025-07-31BUY36659.97061.750 61.572USD 22,535 56.25
2025-07-17BUY1,60957.81058.560 58.485USD 94,102 56.16
2025-06-30SELL-23252.02053.440 53.298USD -12,365 56.24 Profit of 683 on sale
2025-06-25SELL-11652.32053.640 53.508USD -6,207 56.32 Profit of 327 on sale
2025-06-20SELL-23252.81053.750 53.656USD -12,448 56.39 Profit of 635 on sale
2025-05-23BUY11654.54054.680 54.666USD 6,341 56.76
2025-05-19SELL-11653.30053.370 53.363USD -6,190 56.87 Profit of 407 on sale
2025-05-15SELL-34848.95049.700 49.625USD -17,270 56.98 Profit of 2,561 on sale
2025-05-12SELL-11666.58067.900 67.768USD -7,861 57.04 Loss of -1,244 on sale
2025-05-09SELL-11765.87069.940 69.533USD -8,135 56.96 Loss of -1,471 on sale
2025-04-30SELL-11761.42061.800 61.762USD -7,226 56.55 Loss of -609 on sale
2025-04-24SELL-23459.25059.390 59.376USD -13,894 56.40 Loss of -696 on sale
2025-04-17SELL-11758.79059.330 59.276USD -6,935 56.30 Loss of -348 on sale
2025-04-15SELL-35161.28062.140 62.054USD -21,781 56.22 Loss of -2,047 on sale
2025-04-14SELL-35161.39062.130 62.056USD -21,782 56.16 Loss of -2,068 on sale
2025-04-09SELL-46860.65061.440 61.361USD -28,717 56.05 Loss of -2,485 on sale
2025-04-07SELL-81959.35061.820 61.573USD -50,428 55.99 Loss of -4,569 on sale
2025-04-04BUY40959.77060.980 60.859USD 24,891 55.95
2025-03-31BUY11263.81064.070 64.044USD 7,173 55.70
2025-03-19SELL-22464.30064.550 64.525USD -14,454 54.76 Loss of -2,187 on sale
2025-03-14SELL-67262.27062.720 62.675USD -42,118 54.43 Loss of -5,541 on sale
2025-03-13SELL-22461.06061.480 61.438USD -13,762 54.34 Loss of -1,591 on sale
2025-03-12SELL-3,80860.89062.030 61.916USD -235,776 54.24 Loss of -29,230 on sale
2025-03-07SELL-22460.98061.490 61.439USD -13,762 53.92 Loss of -1,684 on sale
2025-03-06SELL-33660.15060.310 60.294USD -20,259 53.82 Loss of -2,174 on sale
2025-03-03SELL-11257.96059.900 59.706USD -6,687 53.60 Loss of -684 on sale
2025-02-28BUY6,60559.15059.160 59.159USD 390,745 53.50
2025-02-26SELL-9357.92058.700 58.622USD -5,452 53.36 Loss of -490 on sale
2025-02-25SELL-27957.99058.980 58.881USD -16,428 53.28 Loss of -1,563 on sale
2025-02-18BUY46557.90058.900 58.800USD 27,342 52.85
2025-02-13BUY9358.61058.720 58.709USD 5,460 52.51
2025-02-12BUY9358.11058.330 58.308USD 5,423 52.40
2025-02-11BUY27957.33057.390 57.384USD 16,010 52.30
2025-02-06BUY83757.94058.200 58.174USD 48,692 51.95
2025-01-27BUY9355.86057.250 57.111USD 5,311 50.98
2024-12-30BUY46547.99048.800 48.719USD 22,654 50.88
2024-12-06BUY37248.40049.050 48.985USD 18,222 51.08
2024-12-05BUY9348.06048.640 48.582USD 4,518 51.19
2024-12-04BUY46548.61049.080 49.033USD 22,800 51.28
2024-11-29BUY46548.20048.810 48.749USD 22,668 51.62
2024-11-27BUY36848.47048.740 48.713USD 17,926 51.89
2024-11-26BUY9247.79048.170 48.132USD 4,428 52.08
2024-11-21BUY46045.70046.120 46.078USD 21,196 52.80
2024-11-20BUY27645.76046.200 46.156USD 12,739 53.20
2024-11-18BUY1,10442.57045.710 45.396USD 50,117 54.38
2024-11-12BUY73659.61062.020 61.779USD 45,469 54.04
2024-11-08BUY46060.98061.190 61.169USD 28,138 53.54
2024-11-07BUY1,38059.65060.950 60.820USD 83,932 53.07
2024-11-06BUY18460.63061.490 61.404USD 11,298 52.44
2024-10-31BUY9250.57051.210 51.146USD 4,705 50.54
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of HALO

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19371,468246613,71260.5%
2025-09-18369,20950726,19450.8%
2025-09-17256,6119,792553,70146.3%
2025-09-16228,40390394,05258.0%
2025-09-15227,697268471,46148.3%
2025-09-12221,090110427,51051.7%
2025-09-11514,0761,959993,63351.7%
2025-09-10166,289386439,00237.9%
2025-09-09273,054401595,14645.9%
2025-09-08673,4827,545952,32470.7%
2025-09-05290,02413,523686,83942.2%
2025-09-04407,7375,358712,76957.2%
2025-09-03550,40413,7061,063,45351.8%
2025-09-02616,27811,835991,44262.2%
2025-08-29269,93076,054395,06868.3%
2025-08-28433,7604,556628,92169.0%
2025-08-271,260,6114,5391,702,44974.0%
2025-08-26588,7022,967980,20060.1%
2025-08-25371,5652,132648,27057.3%
2025-08-22876,545177,5071,274,83468.8%
2025-08-21443,68860,024724,49661.2%
2025-08-20591,075169,034869,55068.0%
2025-08-19935,00612,4211,715,49554.5%
2025-08-18449,8017,338718,19462.6%
2025-08-15329,4697,019525,00662.8%
2025-08-14516,84366,827759,57868.0%
2025-08-13389,9275,826908,60642.9%
2025-08-12781,37413,6031,175,10266.5%
2025-08-11586,47259,410817,35871.8%
2025-08-08285,72819,152668,99942.7%
2025-08-07408,49314863,23347.3%
2025-08-061,204,1564,8502,539,38747.4%
2025-08-05583,0452901,069,04354.5%
2025-08-04177,608200363,85148.8%
2025-08-01207,308307616,18733.6%
2025-07-31622,1231471,098,49656.6%
2025-07-30274,3231,375540,02850.8%
2025-07-29318,0793,010584,12254.5%
2025-07-28194,988129416,26346.8%
2025-07-25115,0240312,07436.9%
2025-07-24144,85426,732266,45354.4%
2025-07-23154,87130,676443,14434.9%
2025-07-22203,2470381,32153.3%
2025-07-21144,9641,656318,07245.6%
2025-07-18136,0301,809379,30135.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.